ALGN•benzinga•
Regeneron Pharmaceuticals To $851? Here Are 5 Other Price Target Changes For Friday
Summary
Morgan Stanley raised the price target on Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) from $625 to $851. Morgan Stanley analyst Matthew Harrison also upgraded the stock from Equal-Weight to Overweight. Regeneron Pharmaceuticals shares rose 0.9% to $714.99 in pre-market trading.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on September 9, 2022 by benzinga